Taiho Pharmaceutical Co., Ltd. の製品パイプライン分析2016

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA70209172)
◆英語タイトル:Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA70209172
◆発行日:2016年9月30日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site LicenseUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Taiho Pharmaceutical Co., Ltd. の製品パイプライン分析2016]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Taiho Pharmaceutical Co., Ltd. – Product Pipeline Review – 2016
Summary

Global Markets Direct’s, ‘Taiho Pharmaceutical Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the Taiho Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Taiho Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Taiho Pharmaceutical Co., Ltd.
- The report provides overview of Taiho Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Taiho Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Taiho Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Taiho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Taiho Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Taiho Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Taiho Pharmaceutical Co., Ltd. Snapshot 6
Taiho Pharmaceutical Co., Ltd. Overview 6
Key Facts 6
Taiho Pharmaceutical Co., Ltd. – Research and Development Overview 7
Key Therapeutic Areas 7
Taiho Pharmaceutical Co., Ltd. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Pipeline Products – Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Pipeline Products – Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Taiho Pharmaceutical Co., Ltd. – Pipeline Products Glance 18
Taiho Pharmaceutical Co., Ltd. – Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Taiho Pharmaceutical Co., Ltd. – Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Taiho Pharmaceutical Co., Ltd. – Early Stage Pipeline Products 22
IND/CTA Filed Products/Combination Treatment Modalities 22
Preclinical Products/Combination Treatment Modalities 23
Taiho Pharmaceutical Co., Ltd. – Drug Profiles 24
(calcium folinate + gimeracil + oteracil + tegafur) – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
(gimeracil + oteracil + tegafur) – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
(tipiracil hydrochloride + trifluridine) – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
bilastine – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
netupitant – Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
TAS-114 – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
TAS-115 – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
TAS-116 – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TAS-117 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
TAS-119 – Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
TAS-120 – Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
TAS-121 – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
TAS-205 – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TAS-303 – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
TAS-3681 – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
TAS-5567 – Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
trabectedin – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Taiho Pharmaceutical Co., Ltd. – Pipeline Analysis 56
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Target 56
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration 58
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type 59
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action 60
Taiho Pharmaceutical Co., Ltd. – Dormant Projects 62
Taiho Pharmaceutical Co., Ltd. – Discontinued Pipeline Products 63
Discontinued Pipeline Product Profiles 64
(gimeracil + oteracil + tegafur) 64
(tipiracil hydrochloride + trifluridine) 64
orantinib 64
suplatast tosilate 64
Taiho Pharmaceutical Co., Ltd. – Company Statement 65
Taiho Pharmaceutical Co., Ltd. – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables
Taiho Pharmaceutical Co., Ltd., Key Facts 6
Taiho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016 9
Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11
Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12
Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13
Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 14
Taiho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 15
Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 16
Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17
Taiho Pharmaceutical Co., Ltd. - Pre-Registration, 2016 18
Taiho Pharmaceutical Co., Ltd. - Phase III, 2016 19
Taiho Pharmaceutical Co., Ltd. - Phase II, 2016 20
Taiho Pharmaceutical Co., Ltd. - Phase I, 2016 21
Taiho Pharmaceutical Co., Ltd. - IND/CTA Filed, 2016 22
Taiho Pharmaceutical Co., Ltd. - Preclinical, 2016 23
Taiho Pharmaceutical Co., Ltd. - Pipeline by Target, 2016 57
Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 58
Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 59
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 61
Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016 62
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016 63
Taiho Pharmaceutical Co., Ltd., Subsidiaries 66

List of Figures
Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016 8
Taiho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016 11
Taiho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016 12
Taiho Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 13
Taiho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016 14
Taiho Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016 16
Taiho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016 56
Taiho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016 58
Taiho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016 59
Taiho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 60

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA70209172 )"Taiho Pharmaceutical Co., Ltd. の製品パイプライン分析2016" (英文:Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。